EGFR and neoplasm: Molecular profiling of DNA extracted from CTCs from non-small cell lung cancer (NSCLC) patients during treatment allowed monitoring of tumor evolution by mutations in the epidermal growth factor receptor (EGFR) gene related or unrelated to therapy resistance[14].